Home Tags Cancer: Prostate

Tag: Cancer: Prostate

The incidence of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) is 17 percent among patients with metastatic castration-resistant prostate cancer

Advanced Prostate Cancer Variant More Common Than Thought

Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17 percent among those with mCRPC
The automated Bone Scan Index is an independent prognostic imaging biomarker of overall survival in metastatic castration-resistant prostate cancer

Automated Bone Scan Index Prognostic for Prostate Cancer

aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer
Among U.S. veterans with low-risk prostate cancer

Conservative Management Up for Low-Risk Prostate CA in Veterans

More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015
Enzalutamide treatment can significantly lower risk of metastasis or death in men with rapidly advancing

Enzalutamide Improves Outcomes for Aggressive Prostate Cancer

Treatment led to 71 percent lower risk of metastasis or death compared to placebo
For prostate cancer survivors

Prostate Cancer Treatment Side Effects Linked to Distress

Those with worse emotional distress also report worse urinary, sexual, bowel functions
Overall survival is increased for African-American men with metastatic castration resistant prostate cancer versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen

ASCO: Overall Survival Up for African-American Men With mCRPC

Improved survival versus Caucasian men treated with docetaxel/prednisone, DP-containing regimen
Prostate-specific antigen levels three months after radiotherapy are strong markers of prostate cancer outcomes for patients with intermediate- and high-risk disease

PSA Level Three Months After Radiation Tx May Predict Outcome

Findings for men with intermediate- and high-risk prostate cancer
Fewer men are being screened for

From 2008 to 2014, Prostate Cancer Testing, Treatment Down

Sharpest decrease seen in privately insured men after 2011
Moderate wine consumption does not seem to impact the risk of prostate cancer

Overall, Drinking Wine Does Not Impact Prostate Cancer Risk

Findings show small increased risk with white wine, decreased risk with red wine
The U.S. Preventive Services Task Force concludes that the decision to undergo periodic prostate-specific antigen screening for prostate cancer should be an individual one for men aged 55 to 69 years. These findings form the basis of a final recommendation statement

USPSTF: Decision to Undergo PSA Screening Should Be Individual

C recommendation for men aged 55 to 69 years; USPSTF recommends against screening for age 70+